Alland Leila 4

What Happened
Leila Alland, a director of Abeona Therapeutics, received a grant of 37,313 restricted shares on January 26, 2026. The Form 4 reports the acquisition price as $0.00 (code A — award/grant). This was an award of restricted stock rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-26; filing date: 2026-01-27 (timely filing).
• Shares granted: 37,313; acquisition price reported: $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: all restricted stock will vest on January 26, 2027.
• Transaction type/code: A (grant/award of restricted stock).

Context
This was a compensation-related grant of restricted stock that vests one year from the grant date. Awards like this typically reflect director compensation and do not indicate an immediate market sale or purchase; the reported acquisition price of $0 reflects the form reporting method, not a market value.